ECSP16024805A - Nuevo compuesto para el tratamiento de hipoglicemia severa - Google Patents

Nuevo compuesto para el tratamiento de hipoglicemia severa

Info

Publication number
ECSP16024805A
ECSP16024805A ECIEPI201624805A ECPI201624805A ECSP16024805A EC SP16024805 A ECSP16024805 A EC SP16024805A EC IEPI201624805 A ECIEPI201624805 A EC IEPI201624805A EC PI201624805 A ECPI201624805 A EC PI201624805A EC SP16024805 A ECSP16024805 A EC SP16024805A
Authority
EC
Ecuador
Prior art keywords
treatment
new compound
severe hypoglycemia
hypoglycemia
severe
Prior art date
Application number
ECIEPI201624805A
Other languages
English (en)
Inventor
Robert Chadwick Cummins
Jorge Alsina-Fernandez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52278803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16024805(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP16024805A publication Critical patent/ECSP16024805A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Removal Of Specific Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un nuevo compuesto útil en el tratamiento de hipoglicemia.
ECIEPI201624805A 2013-12-18 2016-06-16 Nuevo compuesto para el tratamiento de hipoglicemia severa ECSP16024805A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917658P 2013-12-18 2013-12-18

Publications (1)

Publication Number Publication Date
ECSP16024805A true ECSP16024805A (es) 2017-02-24

Family

ID=52278803

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201624805A ECSP16024805A (es) 2013-12-18 2016-06-16 Nuevo compuesto para el tratamiento de hipoglicemia severa

Country Status (26)

Country Link
US (1) US9688736B2 (es)
EP (1) EP3083669A1 (es)
JP (1) JP2017503782A (es)
KR (1) KR20160077215A (es)
CN (1) CN105793282A (es)
AP (1) AP2016009268A0 (es)
AR (1) AR098616A1 (es)
AU (1) AU2014366427B2 (es)
BR (1) BR112016012505A2 (es)
CA (1) CA2928987A1 (es)
CL (1) CL2016001473A1 (es)
CR (1) CR20160223A (es)
DO (1) DOP2016000128A (es)
EA (1) EA201691036A1 (es)
EC (1) ECSP16024805A (es)
HK (1) HK1224303A1 (es)
IL (1) IL245399A0 (es)
MA (1) MA39108A1 (es)
MX (1) MX2016007984A (es)
NZ (1) NZ719451A (es)
PE (1) PE20160787A1 (es)
PH (1) PH12016501184A1 (es)
SG (1) SG11201604232TA (es)
TN (1) TN2016000180A1 (es)
TW (1) TW201609129A (es)
WO (1) WO2015094878A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CA3128922A1 (en) 2019-02-05 2020-08-13 Eli Lilly And Company Glucagon analog agonists and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
US8450270B2 (en) * 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PE20100255A1 (es) 2008-06-17 2010-04-25 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
BRPI0922969A2 (pt) 2008-12-19 2019-09-24 Univ Indiana Res & Tech Corp pró-farmaco de amida baseado na superfamília de glucagon peptídeo.
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
AU2011206979B2 (en) 2010-01-20 2015-09-10 Zealand Pharma A/S Treatment of cardiac conditions
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
JP6054861B2 (ja) * 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
WO2011117417A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
PE20130338A1 (es) 2010-06-24 2013-03-16 Zealand Pharma As Analogos del glucagon
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
BR112013015861A2 (pt) 2010-12-22 2018-06-05 Marcadia Biotech Inc métodos para reduzir ganho de peso ou induzir perda de peso, e para tratar hiperglicemia, reduzir níveis de glicose no sangue, ou normalizar níveis de glicose no sangue.
AU2012208349A1 (en) 2011-01-20 2013-07-18 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
CN103596583B (zh) * 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물

Also Published As

Publication number Publication date
DOP2016000128A (es) 2016-06-30
PH12016501184A1 (en) 2016-07-25
HK1224303A1 (zh) 2017-08-18
AP2016009268A0 (en) 2016-06-30
TN2016000180A1 (en) 2017-10-06
CR20160223A (es) 2016-07-12
AR098616A1 (es) 2016-06-01
US20160311883A1 (en) 2016-10-27
IL245399A0 (en) 2016-06-30
MA39108A1 (fr) 2017-11-30
EA201691036A1 (ru) 2016-12-30
BR112016012505A2 (pt) 2017-09-26
US9688736B2 (en) 2017-06-27
CN105793282A (zh) 2016-07-20
JP2017503782A (ja) 2017-02-02
WO2015094878A1 (en) 2015-06-25
SG11201604232TA (en) 2016-07-28
AU2014366427A1 (en) 2016-05-19
PE20160787A1 (es) 2016-08-17
TW201609129A (zh) 2016-03-16
AU2014366427B2 (en) 2017-02-16
MX2016007984A (es) 2016-09-09
CL2016001473A1 (es) 2017-03-10
CA2928987A1 (en) 2015-06-25
EP3083669A1 (en) 2016-10-26
NZ719451A (en) 2017-10-27
KR20160077215A (ko) 2016-07-01

Similar Documents

Publication Publication Date Title
UY34654A (es) Inhibidores de la beta-secretasa
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
IN2013DE00266A (es)
AR097668A1 (es) Colorante-polímero
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
DOP2016000067A (es) Nuevo inhibidor de sglt1
CL2016000171A1 (es) Formulación de metaxalona.
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
BR112015021575A2 (pt) composição fungicida
IN2013MU03768A (es)
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия
CL2012000641S1 (es) Lavamanos.
TH127247B (th) องค์ประกอบสำหรับการปรับปรุงสภาพของผิวหนัง
TN2011000399A1 (fr) دراجة كهربائية ذات شحن الي
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه